Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016 - Focus on 8 Companies & 15 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016" report to their offering.

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities

Institutes. Toll Like Receptor 3 - Pipeline Review, H2 2016, outlays comprehensive information, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection.

It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Toll Like Receptor 3 Overview
  3. Therapeutics Development
  4. Pipeline Products for Toll Like Receptor 3 - Overview
  5. Pipeline Products for Toll Like Receptor 3 - Comparative Analysis
  6. Toll Like Receptor 3 - Therapeutics under Development by Companies
  7. Toll Like Receptor 3 - Therapeutics under Investigation by Universities/Institutes
  8. Toll Like Receptor 3 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Toll Like Receptor 3 - Products under Development by Companies
  13. Toll Like Receptor 3 - Products under Investigation by Universities/Institutes
  14. Toll Like Receptor 3 - Companies Involved in Therapeutics Development
  • Biomics Biotechnologies Co., Ltd.
  • Hemispherx Biopharma, Inc.
  • Idera Pharmaceuticals, Inc.
  • Innate Pharma S.A.
  • Johnson & Johnson
  • MultiCell Technologies, Inc.
  • Oncovir, Inc.
  • Tollys S.A.S

For more information about this report visit http://www.researchandmarkets.com/research/wnk2wv/toll_like

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs